TearLab names Adam Szaronos president and CEO, and Jim Mazzo executive chairman of the Board

,

TearLab Corp. announced that Adam Szaronos has been appointed president and CEO by the company's Board of Directors, effective immediately.

TearLab Corp. announced that Adam Szaronos has been appointed president and CEO by the company's Board of Directors, effective immediately.

Jim Mazzo, an ophthalmic industry business leader with more than 40 years' experience, and internationally renowned for building and running organizations, was also appointed as executive chairman of TearLab's Board of Directors, effective immediately.

Szaronos has been instrumental in leading teams and bringing innovations to market to address unmet needs throughout eye care. He joined TearLab's executive team as Chief Commercial Officer in 2020 after the company was acquired by investment firm Accelmed Partners. In that role, he was responsible for overseeing the commercial restructuring and relaunch of TearLab's global diagnostics business.

Prior to TearLab, Szaronos held various sales, marketing, and strategic management positions of increasing responsibility at Alcon, with leadership experience throughout both the surgical and vision care businesses. His most recent role was as Alcon's Head of Dry Eye Devices, where he launched and managed the company's new business unit.

"I am extremely pleased and proud to be taking the helm of this great organization. This company is forged on a strong customer-focused foundation, with a proven ability to pioneer new innovations and categories," Szaronos said in a statement. "That's a winning model I want us to continue building upon as we expand our current diagnostics business and bring new technologies to market for our customers."

Szaronos noted that the company now is positioned to execute its growth strategy with a focus on the evolving needs of its eye care partners and the millions of current patient care decisions they trust TearLab’s technology to help support.

Osmolarity testing enables clinicians to detect visually significant ocular surface disease, and is considered an essential test by the American Society of Cataract and Refractive Surgery. Abnormal osmolarity can adversely impact accuracy of refractive measurements and the TearLab osmolarity test empowers clinicians to accurately diagnose dry eye disease. It is established, with over 20 million tests performed in 50 countries worldwide.